COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

NCT05081388 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

SARS-CoV-2

Interventions

DRUG: REGN14256
DRUG: imdevimab
DRUG: casirivimab + imdevimab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals